AU2001294511A1 - New strategy for leukemia therapy - Google Patents

New strategy for leukemia therapy

Info

Publication number
AU2001294511A1
AU2001294511A1 AU2001294511A AU9451101A AU2001294511A1 AU 2001294511 A1 AU2001294511 A1 AU 2001294511A1 AU 2001294511 A AU2001294511 A AU 2001294511A AU 9451101 A AU9451101 A AU 9451101A AU 2001294511 A1 AU2001294511 A1 AU 2001294511A1
Authority
AU
Australia
Prior art keywords
new strategy
leukemia therapy
leukemia
therapy
strategy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294511A
Inventor
Paolo Vigneri
Jean Y. J. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001294511A1 publication Critical patent/AU2001294511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2001294511A 2000-06-30 2001-06-29 New strategy for leukemia therapy Abandoned AU2001294511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21559500P 2000-06-30 2000-06-30
US60215595 2000-06-30
PCT/US2001/020602 WO2002000024A1 (en) 2000-06-30 2001-06-29 New strategy for leukemia therapy

Publications (1)

Publication Number Publication Date
AU2001294511A1 true AU2001294511A1 (en) 2002-01-08

Family

ID=22803600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294511A Abandoned AU2001294511A1 (en) 2000-06-30 2001-06-29 New strategy for leukemia therapy

Country Status (3)

Country Link
US (2) US7238525B2 (en)
AU (1) AU2001294511A1 (en)
WO (1) WO2002000024A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510733A (en) * 2000-10-05 2004-04-08 ダレイ，　ジョージ　キュー． Methods for inducing cancer cell death and tumor regression
ATE359790T1 (en) * 2001-05-16 2007-05-15 Novartis Pharma Gmbh COMBINATION OF N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO -2-METHYLPHENYL -4-(3-PYRIDIL)-2PYRIMIDINE-AMINE WITH A BIPHOSPHONATE
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
DE10248751A1 (en) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslocation molecules and their use
US20050203174A1 (en) * 2004-03-09 2005-09-15 Kosan Biosciences, Inc. Combination therapies using leptomycin B
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
AU2006278514A1 (en) * 2005-08-03 2007-02-15 Mia Levite Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells by dopamine D1R agonists
US8003687B2 (en) 2005-09-12 2011-08-23 Kosan Biosciences Incorporated Esters of compounds in the leptomycin family
US20100152198A1 (en) * 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
JP2010519337A (en) * 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド Carbamate compounds
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2010012703A (en) 2008-05-21 2010-12-21 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors.
WO2010039275A1 (en) * 2008-10-03 2010-04-08 Oligonix, Inc. Method, array and system for detecting intergenic fusions
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers

Also Published As

Publication number Publication date
US7238525B2 (en) 2007-07-03
US20070299097A1 (en) 2007-12-27
WO2002000024A1 (en) 2002-01-03
WO2002000024A8 (en) 2002-03-21
US20030162740A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU2002222853A1 (en) Therapeutic compounds
AU2002225730A1 (en) Compounds
AU2001280796A1 (en) Electrowetting-driven micropumping
AU2001262847A1 (en) Language-understanding
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001294511A1 (en) New strategy for leukemia therapy
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001265089A1 (en) Rc-timer scheme
AU2001258349A1 (en) Bisacylguanidine
AU4430701A (en) Compounds for targeting
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001258924A1 (en) Microsatellite-aflp
AU2002225724A1 (en) Motilide compounds
AU2001220281A1 (en) Rollerboard for road-skiing
EP1185135A3 (en) Chinguard for headphone
AU2002220684A1 (en) Fap-alpha-activated anti-tumor compounds
AU2002217285A1 (en) Compounds
AU2001246864A1 (en) Hypotensors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001262711A1 (en) Cytoprotectors
AU2001260192A1 (en) Glycinamides
AU2001292897A1 (en) Novel therapy
AU2002216043A1 (en) Compounds